Revolution Medicines, Inc.
daraxonrasib
metastatic pancreatic ductal adenocarcinoma
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on daraxonrasib for metastatic pancreatic ductal adenocarcinoma is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Based on these results, Revolution Medicines intends to submit these data to global regulatory authorities, including to the U.S. Food and Drug Administration (FDA) as part of a future New Drug Application under a Commissioner’s National Pr”